Education
-
Fellowship, Infectious Diseases, University of Illinois at Chicago/University of Illinois Hospital, Chicago, IL
-
PGY-1 Pharmacy Practice Residency, Mann-Grandstaff VA Medical Center, Spokane, WA
-
PharmD, Washington State University, Spokane, WA
-
BS, Biology, Brigham Young University, Provo, UT
Research Interests
- Multi-drug resistant Gram-negative bacteria
- Antimicrobial pharmacokinetics/pharmacodynamics
- Epidemiology and outcomes research through healthcare databases
- Novel approaches to translational, clinical, and patient-centered outcomes research
Select Publications
Wenzler E, Butler D, Tan X, Katsube T, Wajima T. Pharmacokinetics, pharmacodynamics, and dose optimization of cefiderocol during continuous renal replacement therapy. Clinical Pharmacokinetics. 2022;61(4):539-552. DOI: 10.1007/s40262-021-01086-y
Butler DA, Rana AP, Krapp F, et al. Optimizing aminoglycoside selection for KPC-producing Klebsiella pneumoniae with the aminoglycoside-modifying enzyme (Ame) gene aac(6’)-Ib. Journal of Antimicrobial Chemotherapy. 2021;76(3):671-679. DOI: 10.1093/jac/dkaa480
Butler DA, Biagi M, Gupta V, et al. Development of a 51-hospital Chicagoland regional antibiogram and comparison to local hospital and national surveillance data. Infection Control and Hospital Epidemiology. 2020;41(12):1409-1418. DOI: 10.1017/ice.2020.334
Butler DA, Biagi M, Tan X, Qasmieh S, Bulman ZP, Wenzler E. Multidrug Resistant Acinetobacter baumannii: Resistance by Any Other Name Would Still Be Hard to Treat. Current Infectious Disease Reports. 2019. DOI: 10.1007/s11908-019-0706-5.
Biagi M, Wu T, Lee M, Patel S, Butler D, Wenzler E. Searching for the Optimal Treatment for Metallo- and Serine-β-Lactamase Producing Enterobacteriaceae: Aztreonam in Combination with Ceftazidime-Avibactam or Meropenem-Vaborbactam. Antimicrobial Agents and Chemotherapy. 2019. DOI: 10.1128/AAC.01426-19.
Biagi M, Butler D, Tan X, Qasmieh S, Tejani K, Patel S, Rivosecchi RM, Nguyen MH, Shields RK, Wenzler E. Pharmacokinetics and Dialytic Clearance of Isavuconazole During in vitro and in vivo Continuous Renal Replacement Therapy. Antimicrobial Agents and Chemotherapy. 2019. DOI: 10.1128/AAC.01085-19.
Biagi MJ, Butler DA, Tan X, Qasmieh S, Wenzler E. A Breath of Fresh Air in the Fog of Antimicrobial Resistance: Inhaled Polymyxins for Gram-negative Pneumonia. Antibiotics (Basel) 2019 Mar 16;8(1). pii: E27. DOI: 10.3390/antibiotics8010027
Biagi MJ, Butler DA, Wenzler E. AUC-Based Monitoring of Vancomycin: Closing the Therapeutic Window. The Journal of Applied Laboratory Medicine. 2019. DOI: 10.1373/jalm.2018.027391
Conferences and Presentations
Gifford M, McCray D, Moolick K, Butler DA. Compatibility of Omadacycline with Select Parenteral Products in Simulated Y-Site Administration. ASM Microbe 2022. Washington, DC.
Gavaghan V, Lee M, Butler DA, Biagi M, Santarossa M, Harrington A, Albarillo F, Wenzler E. Clinical outcomes in patients with carbapenem-non-susceptible, β-lactam-susceptible Pseudomonas aeruginosa infections. Submitted. IDWeek 2019. Washington, DC.
Butler DA, Biagi M, Tan X, Qasmieh S, Wenzler E. Isavuconazole clearance during in vitro and in vivo continuous renal replacement therapy. 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 2019, Amsterdam, Netherlands.
Butler DA, Biagi M, Tan X, Qasmieh S, Wieczorkiewicz S, Gupta V, Young L, Patel U, Naegele S, Santarossa M, Harrington A, Postelnick M, Mira Suseno, Christensen A, Giddens J1, Murrey T, Hanson A, Sam S, Pettit N, Danziger L, Wenzler E. Evaluation of a Chicagoland Regional Antibiogram. 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 2019, Amsterdam, Netherlands.
Butler DA, Fiorella K. Lopez, Amisha Rana, Alan R. Hauser, Zackery P. Bulman. Optimizing Aminoglycoside Selection for KPC-Producing Klebsiella pneumoniae with Aminoglycoside Modifying Enzyme AAC(6’)-Ib. 2018 ESCMID/ASM Conference on Drug Development. September 2018, Lisbon, Portugal.